



Issue of Shares and Cleansing Notice

NEW YORK and SYDNEY, Australia, 15 June 2026 - Beroni Group (NSX: BTG) ("Beroni" or the "Company"), advises that the Company has issued 4,315,000 ordinary shares to directors and employees as approved by shareholders at the Annual General Meeting held on 29 May 2026.

Confirmation under section 708A(5)(e) of the Corporations Act 2001 (Cth)

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

1. the Company issued the Shares without disclosure to investor under Part 6D.2 of the Corporations Act;
2. this notice is given under section 708A(5)(e);
3. as at the date of this notice, the Company has complied with:
 - a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b) section 674 and section 674A of the Corporations Act; and
4. as at the date of this notice, there is no information that is "excluded information" (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company in accordance with section 708A(5)(e) of the Corporations Act.

-End-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

For more information, please contact us at:

Tel: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com